Compare Novavax Inc (NVAX) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Novavax Inc trades at $7.97 (market cap $1.31B), while iShares 1 3 Year Treasury Bond ETF trades at $81.93. The key difference: Novavax Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVAX | SHY | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Fixed Income |
52-Week High | $11.19 | $83.18 |
52-Week Low | $6.22 | $81.77 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.92, up 0.08% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights institutional buying interest amid fluctuating Treasury yields driven by inflation data and geopolitical tensions.
The outlook for SHY is influenced by Federal Reserve policy expectations and inflation trends. Opportunities include its role as a short-duration bond haven during volatility, but risks involve rising yields pressuring prices and macroeconomic uncertainty. Investors should weigh interest rate sensitivity against current institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
